Clinical Trials

NICE Recommends AstraZeneca's Imfinzi with Chemo for Resectable NSCLC
Research & Development NICE Recommends AstraZeneca's Imfinzi with Chemo for Resectable NSCLC

The recent endorsement by the National Institute for Health and Care Excellence (NICE) to utilize AstraZeneca's Imfinzi (durvalumab) in combination with chemotherapy as a treatment for adults with resectable non-small cell lung cancer (NSCLC) marks a significant milestone in cancer care. This

Can POLB 001 Revolutionize CRS Treatment in Cancer Immunotherapy?
Research & Development Can POLB 001 Revolutionize CRS Treatment in Cancer Immunotherapy?

In a significant breakthrough, Poolbeg Pharma announced positive pre-clinical study results for their drug POLB 001, presented at the 66th American Society of Hematology (ASH) Annual Meeting. The study focused on the drug's potential to prevent Cytokine Release Syndrome (CRS), a frequently observed

USC Awarded $3.4M to Tackle Cognitive Decline in Aging Women
Research & Development USC Awarded $3.4M to Tackle Cognitive Decline in Aging Women

The Keck School of Medicine of USC has embarked on a groundbreaking research initiative aimed at addressing age-related cognitive decline in women. This significant effort is led by Dr. Young-Kwon Hong and has been bolstered by securing a $3.4 million federal grant from the Advanced Research

Can Innovative Tech Improve Long-Term Outcomes in Pediatric AE?
Research & Development Can Innovative Tech Improve Long-Term Outcomes in Pediatric AE?

Autoimmune encephalitis (AE), a condition where the body's immune system turns against the brain, affects approximately one-third of global encephalitis cases and often leads to debilitating symptoms, including seizures, cognitive impairment, and motor dysfunctions. Despite advancements in

How Will New HIV Guidelines Change Treatment and Prevention?
Research & Development How Will New HIV Guidelines Change Treatment and Prevention?

The International Antiviral (formerly AIDS) Society-USA (IAS-USA) has unveiled comprehensive international guidelines for the treatment and prevention of HIV, coinciding with the observance of World AIDS Day on December 1, 2024. These guidelines were meticulously developed by a panel of volunteer

Can GLP-1 Receptor Agonists Transform MASLD Treatment Effectiveness?
Research & Development Can GLP-1 Receptor Agonists Transform MASLD Treatment Effectiveness?

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), previously known as nonalcoholic fatty liver disease, has become a major global health concern. Characterized by hepatic steatosis and associated with at least one cardiometabolic risk factor such as type 2 diabetes mellitus (T2DM),

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later